Asset Publisher

null Josep Mallolas´s group


Coinfection with hepatitis B or C, Pharmacokinetics of antiviral agents
Our research group has been working in this field for the last 12 years, focused on two topics of HIV reseach:

  1. Coinfection of HIV and hepatotropic viruses.
  2. Pharmacokinetics of antirretroviral agents.

Although sometimes the research have been exclusively in one of both topics, there are some projects which include differents aspects of both fields.

Coinfection of HIV and hepatotropic viruses  
Our group has been involved in pivotal studies from more than 10 years ago including clinical trials comparing standard of care vs new approaches for the treatment of hepatitis C in HIV patients as well as new non-invasive tools for the assessment of liver fibrosis, pharmacokinetc studies of antirretrovirals in coinfected patients, toxicity of antiretrovirals and drugs for HCV therapy,…etc.

Pharmacokinetics of antiretroviral agents  
Like in the first topic we have been actively engaged in this topic including studies focused on the main pharmacokinetics aspects of antiretroviral agents with special attention to those with clinical implication in general HIV population and in pregnant women. We have funding supports from several public agencies: Mainly FISS and FIPSE and also from majority of private laboratories of antiviral agents.

Related Assets


Josep Mallolas
Pilar Callau
Montserrat Laguno
María Martínez
Amparo Tricas

Related Assets

Related Assets


  • Fat redistribution syndromes associated with HIV-1 infection and combination antiretroviral therapy. 
    Domingo P, Estrada V, López-Aldeguer J, Villaroya F, Martínez E.  AIDS Rev 2012; 14: 112-123. 
  • Hepatic safety of efavirenz in HIV/hepatitis C co-infected patients with advanced liver fibrosis. 
    Pineda J, Neukam K, Mallolas J et al.  Journal of Infection 2012; 64: 204-211. 
  • Liver toxicity of initial antiretroviral drug regimens including two nucleoside analogs plus one non-nucleoside analog or one ritonavir-boosted protease inhibitor in HIV/HCV- coinfected patients. 
    Macías J, Neukam K, Mallolas J et al.  HIV Clin Trials 2012; 13: 61-69. 
  • Sustained virological response to interferon plus ribavirin reduces non-liver related mortality in patients coinfected with HIV and hepatitis C virus. 
    Berenguer J, Rodríguez E, Miralles P, Von Wichmana MA, López-Aldeguer J, Mallolas J et al.  Clin Infec Dis 2012; 55 (5): 728-36. 
  • harmacogenetics of efficacy and safety of HCV treatment in HCV-HIV coinfected patients: significant associations with IL28B and SOCS3 gene variants. 
    PVidal F, López-Dupla M, Laguno M, Veloso S, Mallolas J et al.  Plos ONE 2012; 7(11): e47725. 
  • Low rate of sustained virological response in an outbreak of acute hepatitis C in HIV-infected patients. 
    Laguno M, Martínez-Rebollar M, Pérez I, Costa J, Larrousse M, Calvo M, Loncà M, Muñoz A, González-Cordón A, Blanco JL, Martínez E, Gatell JM, Mallolas J.  AIDS Research and Human Retroviruses 2012; 28: 1294-1300 
  • The European AIDS Treatment Network (NEAT) acute hepatitis C infection consensus panel. Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference. 
    (Mallolas J pertenece a este panel)  AIDS 2011; 25: 399-40. 
  • Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. 
    Berenguer J, von Wichmann MA, Quereda C, Miralles P, Mallolas J et al.  J Antimicrob Chemother 2011; 66: 2843-2849. 
  • Pharmacokinetic study of saquinavir 500 mg plus ritonavir (1000/100 mg twice a day) in HIV-positive pregnant women. 
    Martínez-Rebollar M, Loncà M, Pérez I, Soy D, Brunet M, Martín R, Coll O, Hernández S, Laguno M, Milinkovic A, Larrousse M, Calvo M, Blanco JL, Martínez E, Gatell JM, Mallolas J.  Ther Drug Monit 2011; 33: 772-777. 
  • Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. 
    Laguno M, Larrousse M, Murillas J, Blanco JL, León A, Milinkovic A, Martínez E, Sánchez-Tápias JM, de Lazzari E, Gatell JM, Costa J, Mallolas J  J. Acquir Immune Defic Syndr 2007; 44: 174-178. 
  • Pharmacokinetic interaction between rifampicin and ritonavir boosted atazanavir in HIV infected patients. 
    Mallolas J, Sarasa M, Nomdedeu M, Soriano A, López-Púa Y, Blanco JL et al.  HIV Medicine 2007; 8: 131-134. 

Related Assets